

A photograph of a woman with blonde hair hugging a young girl with dark hair. The woman is wearing a beige knitted sweater and a large ring. The girl is wearing a white shirt with small yellow flowers. The background is blurred, showing a plant and a wall.

Nobelpharma

Nobelpharma develops medications and medical devices for underserved patient populations.

Visit us at nobelpharma-us.com for more information about our mission and approach to product development.

A Leader in Scientific Advancement

Who We Are

Nobelpharma America, LLC is the first global subsidiary of Nobelpharma Co., Ltd., headquartered in Tokyo, Japan. Nobelpharma develops critical but neglected pharmaceuticals and medical devices.

Our company name comes from Alfred Nobel, the founder of the Nobel Prize. We are proud to be part of Alfred Nobel's innovative and scientific legacy. His groundbreaking achievements continue to inspire our company's mission and values.



Priorities

Nobelpharma is committed to meeting essential patient needs by developing treatments for diseases that often go overlooked because of the small number of patients affected.

No one should have to experience the anxiety and vulnerability that comes with a condition that can be difficult to treat or manage.

Our Leadership

U.S. Leadership



“Nobelpharma is committed to advancing scientific understanding and delivering new options to individuals and families. We value learning from the patient community to help shape the future of our research and development.”

Masa Onozaki, President & CEO of Nobelpharma America, LLC

Global Leadership



“Nobelpharma's commitment to patients across the world reflects our desire to serve underserved patient communities.”

Jin Shiomura, President & CEO of Nobelpharma Co., Ltd.


Patients First

Nobelpharma's unique "patients first" approach to product development targets medical conditions that have limited or no treatment options or may go overlooked because of the small number of patients affected.

Nobelpharma aspires to provide hope to families who live with rare diseases. Our commitment extends from the patients and their families to the communities affected by rare diseases as well as the advocacy associations that help them.



Timeline of Success



Research and Development

We strive to bring innovative products to market as quickly as possible, hoping to provide patients and physicians with treatment options for underserved patient populations.

The Nobelpharma America pipeline includes potential treatments for conditions that have little or no other treatment options in the U.S.

Tympanic membrane perforation (TMP)

(NPC-18)* is a drug approved in Japan for the treatment of **tympanic membrane perforation**.

Nobelpharma received approval in Japan (2019)*

Adductor spasmodic dysphonia

(NPC-17)* is a medical device approved in Japan for type II thyroplasty for the treatment of **adductor spasmodic dysphonia**.

Nobelpharma received approval in Japan (2018)*

*NPC-17 and NPC-18 are products approved in Japan only, and have not been approved or deemed safe and effective by the FDA, and are not available for commercial sale in the U.S. NPC-17 and NPC-18 are investigational only in the US.

This document contains information about products that may not be available in the U.S. Nothing contained herein should be considered a solicitation, promotion, or advertisement for any product including those under development.

Nobelpharma America, LLC
Bethesda, MD
301-244-5951

 nobelpharma-us.com

 [@NobelpharmaUS](https://twitter.com/NobelpharmaUS)

 [Nobelpharma America, LLC](https://www.linkedin.com/company/nobelpharma-america)

 [Nobelpharma America](https://www.facebook.com/NobelpharmaAmerica)